The Obsessive-Compulsive Disorder drugs in development market research report provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Obsessive-Compulsive Disorder. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued products.

GlobalData tracks nine drugs in development for Obsessive-Compulsive Disorder by nine companies/universities/institutes. The top development phase for Obsessive-Compulsive Disorder is preclinical with four drugs in that stage. The Obsessive-Compulsive Disorder pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Obsessive-Compulsive Disorder pipeline products market are: Biogen, Omeros and Rugen Therapeutics R&D (Shanghai).

The key targets in the Obsessive-Compulsive Disorder pipeline products market include Glutamate Ionotropic Receptor NMDA Type Subunit (NMDAR or GRIN), Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B), and Excitatory Amino Acid Transporter 2 (Glutamate/Aspartate Transporter II or Sodium Dependent Glutamate/Aspartate Transporter 2 or Solute Carrier Family 1 Member 2 or SLC1A2).

The key mechanisms of action in the Obsessive-Compulsive Disorder pipeline product include 5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A) Agonist with one drug in Phase II. The Obsessive-Compulsive Disorder pipeline products include five routes of administration with the top ROA being Oral and two key molecule types in the Obsessive-Compulsive Disorder pipeline products market including Small Molecule, and Monoclonal Antibody.

Obsessive-Compulsive Disorder overview

Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead the patient to perform repetitive behaviors (compulsions). Symptoms include having repeated thoughts or mental images about certain things, such as fears of germs, dirt, intruders, acts of violence, or hurting loved ones; and doing the same rituals over and over, such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. Risk factors include family history. Treatment includes antidepressants and psychiatric medications.

For a complete picture of Obsessive-Compulsive Disorder’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.